Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Hopes To Dodge New Trial With CF Antibiotic

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s complete response finds the Cayston NDA not approvable as is.

You may also be interested in...



FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter

Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.

FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter

Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.

With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene

Disease-oriented foundations and cash-strapped biotechs are increasingly seeking common ground: as more becomes known about the mechanisms by which a given disease operates, foundation boards are finding more opportunities to fund promising start-ups and established biotechs.

Related Content

Topics

UsernamePublicRestriction

Register

PS068351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel